FDA Grants Breakthrough Status to LSD-Based Anxiety Drug

A single dose of MM120 shows significant promise in treating generalized anxiety disorder, with the FDA expediting its development.

A groundbreaking study reveals a single dose of LSD-based drug MM120 significantly reduces anxiety symptoms, marking a potential shift in mental health treatment.
The FDA grants 'breakthrough therapy' status to MM120 for treating generalized anxiety disorder, expediting the development and review process.
Clinical trials show a 48% remission rate in generalized anxiety disorder symptoms 12 weeks after a single dose of MM120, with 65% of patients experiencing improvements.
Adverse effects of MM120 are generally mild to moderate and transient, occurring mostly on the day of administration.
MM120 also shows promise in treating depression symptoms, expanding the potential impact of psychedelic therapy in mental health care.